2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123241
    ZINC08792229 904514-73-4 98%
    ZINC08792229 is a potent SIRT1 inhibitor. ZINC08792229 has the potential for research on SIRT1 related diseases, such as ageing, diabetes, cancers.
    ZINC08792229
  • HY-123273
    (Rac)-Metyrapol 17159-42-1 98%
    Metyrapol is a steroid 11β-hydroxylase inhibitor. Metyrapol blocks the conversion of deoxycorticosterone to corticosterone in rat adrenal homogenates. Metyrapol can be used in the study of metabolic diseases.
    (Rac)-Metyrapol
  • HY-123294
    Fentrazamide 158237-07-1 98%
    Fentrazamide (YRC 2388) is a herbicide. Fentrazamide has specific toxic effects on the nervous system and erythrocytes in rats, affecting the energy supply of cells mainly by interfering with the glycolysis process. Fentrazamide can be used as a useful tool to study the mechanisms of neurodegenerative diseases and erythrocyte dysfunction.
    Fentrazamide
  • HY-123370
    FR-167356 174185-16-1 98%
    FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss.
    FR-167356
  • HY-123394
    AP-22161 268741-42-0 98%
    AP22161 is a potent and selective Src SH2 domain inhibitor with an IC50 of 0.24 µM. AP22161 exhibits >120-fold selectivity over Yes SH2 (IC50 = 29.38 µM) and ZAP SH2 (IC50 = 421.86 µM). AP22161 inhibits Src-dependent cellular activity and diminishes osteoclast resorptive activity. AP22161 can be used for osteoporosis research.
    AP-22161
  • HY-123421
    UK-9040 47453-14-5 98%
    UK-9040, a derivative of the antihistamine Triprolidine (HY-B1808), is an orally active inhibitor of gastric secretory. UK-9040 reduces gastric acid, pepsin, and volume output in response to food, Insulin (HY-P0035), Histamine (HY-B1204), N-methyl histamine, and Pentagastrin (HY-A0261).
    UK-9040
  • HY-123435
    RWJ 22108 112769-37-6 98%
    RWJ 22108 is a bronchoselective calcium channel blocker, with the IC50 of 5.7 nM in calcium-dependent contraction of canine bronchiolar smooth muscle.
    RWJ 22108
  • HY-123566
    PSD-506 754177-77-0 98%
    PSD-506 (RO 3202904) is a muscarinic M2/M3 antagonist. PSD-506 has the potential to be used in studies of bladder overactivity and urinary incontinence.
    PSD-506
  • HY-12357R
    Bempedoic acid (Standard) 738606-46-7 98%
    Bempedoic acid (Standard) is the analytical standard of Bempedoic acid. This product is intended for research and analytical applications. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor. Bempedoic acid (ETC-1002) activates AMPK.
    Bempedoic acid (Standard)
  • HY-123642
    BLXA-4-ME 362516-29-8 98%
    BLXA-4-ME is used for gingivitis study.
    BLXA-4-ME
  • HY-123705
    Ronifibrate 42597-57-9 98%
    Ronifibrate is a fibrate and a PPARα activator. Ronifibrate can be studied in research on hyperlipidemia.
    Ronifibrate
  • HY-123765
    JTT-553 701232-94-2 98%
    JTT-553 is a DGAT1 inhibitor (IC50: 2.38 nM). JTT-553 reduces plasma concentrations of glucose, insulin, non-esterified fatty acids (NEFA), total cholesterol (TC), and hepatic triglycerides (TG). JTT-553 improves insulin-dependent glucose uptake and glucose intolerance in adipose tissue of DIO mice. JTT-553 reduces TNF-α mRNA levels and increases GLUT4 mRNA levels in adipose tissue of KK-Ay mice. JTT-553 improves adipose tissue insulin resistance and systemic glucose metabolism by reducing body weight. JTT-553 can be used in the study of obesity and type 2 diabetes mellitus (T2DM).
    JTT-553
  • HY-123782
    (Rac)-UK-414495 337962-93-3 98%
    (Rac)-UK-414495 (example 7) is a potent neutral endopeptidase (NEP) inhibitor. (Rac)-UK-414495 causes potentiation of cAMP in the sexual genitalia of the female.
    (Rac)-UK-414495
  • HY-123871
    AS2575959 sodium 1616871-34-1 98%
    AS2575959 (sodium) is an agonist of GPR40. AS2575959 (sodium) can enhance glucose metabolism and has synergic effect with Sitagliptin (HY-13749) on insulin as well as incretin secretion. AS2575959 (sodium) can be studied in research on type 2 diabetes.
    AS2575959 sodium
  • HY-123928
    Contilisant 2135615-68-6 98%
    Contilisant is a permeable antioxidant and neuroprotectant agent. Contilisant exhibits high nM affinity at H3R. Contilisant inhibits monoamine oxidases and cholinesterases. Contilisant has a binding affinity of 65.23 nM towards hS1R. Contilisant can significantly restore cognitive deficit induced by Aβ1-42 in the radial maze assay of Alzheimer’s animal model.
    Contilisant
  • HY-123965
    PF-06745013 2089334-01-8 98%
    PF-06745013 (Compound 37) is a MAP4K4 inhibitor without time-dependent inhibition (TDI) risk of CYP3A4 (IC50 of 0.4  nM for MAP4K4). PF-06745013 has no accumulation CNS-impaired and non-ATP competitive activities in mouse models. PF-06745013 can be used for inflammatory diseases like diabetes and cancers research.
    PF-06745013
  • HY-123974
    BR101549 2252478-54-7 98%
    BR101549 is a non-TZD agonist of PPARγ. BR101549 activates PPARγ to the level of Pioglitazone in vitro. BR101549 can control blood glucose level in mouse model. BR101549 can be studied in anti-diabetic research.
    BR101549
  • HY-124015
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one 177987-23-4 98%
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one (Compound 1) is an inhibitor of oleamide hydrolase.
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one
  • HY-124085
    Prostaglandin F1α alcohol 13487-47-3 98%
    Prostaglandin F1α alcohol is an analog of PGF1α.
    Prostaglandin F1α alcohol
  • HY-124104
    Aldicarb sulfoxide 1646-87-3 98.41%
    Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish.
    Aldicarb sulfoxide
Cat. No. Product Name / Synonyms Application Reactivity